Deleobuvir Sodium

N/A

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameDeleobuvir Sodium
Drug Alias Namedeleobuvir迪来布韦deleobuvirum德莱布韦得利奥布韦 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsRenal InsufficiencyHepatitis C, ChronicHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International Gmbh +[4] 
Active IndicationsN/A
Inactive IndicationsRenal InsufficiencyHepatitis C, ChronicHepatitis C

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG